When whales move millions in Ripple (XRP), the crypto market is all aflutter with speculation, but the wisest opportunities usually hide off the radar of hype-driven trades. Mutuum Finance (MUTM) is turning out to be one such high-potential gem, currently in the middle of Phase 6 of its presale, at a mere $0.035, and already […]When whales move millions in Ripple (XRP), the crypto market is all aflutter with speculation, but the wisest opportunities usually hide off the radar of hype-driven trades. Mutuum Finance (MUTM) is turning out to be one such high-potential gem, currently in the middle of Phase 6 of its presale, at a mere $0.035, and already […]

The Cryptocurrencies to Add to Your Portfolio Now as Ripple (XRP) Sees Major $55.8M Whale Transfer

2025/10/10 04:00
4 min read

When whales move millions in Ripple (XRP), the crypto market is all aflutter with speculation, but the wisest opportunities usually hide off the radar of hype-driven trades. Mutuum Finance (MUTM) is turning out to be one such high-potential gem, currently in the middle of Phase 6 of its presale, at a mere $0.035, and already over 60% sold out. 

MUTM offers real DeFi utility through a dual-lending protocol, with real-world applications for decentralized finance users as well as early investors a chance for asymmetrical upside in the thousands. With presale mania underway and use case in the real world about to go live, Mutuum Finance is likely to be a watch project for those who wish to get ahead of the next crypto wave. 

XRP Records $55.8M Whale Transfer as Market Considers Key Resistance

Ripple (XRP) is hogging the headlines with a behemoth $55.8 million on-chain transaction, highlighting strategic moves by leading holders and forecasting potential future price action. The token is holding the $3.00 psychological resistance, at about $3.05, backed by strong volume of 6.04 billion, showing ongoing buyer demand. Support near $2.95 has withstood repeated tests, while the proximate resistance near $3.05 could, upon breaking, set the stage for $3.10–$3.15. With analysts waiting on this key level, investors looking for early-stage investments with real use and long-term growth potential are increasingly attracted to Mutuum Finance (MUTM).

Mutuum Finance Presale Goes Wild As Interest Continues To Grow

Mutuum Finance (MUTM) is expanding fast with Phase 6 of its presale already securing over $17 million and 16820 unique holders. MUTM is over 60% sold out in phase 6, and thus, the investors have fewer days to wait until the end of the phase. The early birds are positioning themselves for potentially astronomical gains when the token starts trading on the open market. In addition to the presale, Mutuum Finance also has a fully featured DeFi platform in the works, e.g., the soon-to-launch USD-pegged stablecoin on the Ethereum blockchain.

Mutuum Finance protocol close-order book design is built in order to control market risk and prevent illiquidity. Key variables such as close-level conditions, liquidation levels, and liquidator incentives are tuned to make lending secure and predictable. Liquidation ratios and LTV are constantly tweaked based on the volatility of the asset, with risk assets having tighter loan terms. Along with this, risk-weighted multipliers are applied across asset classes that give ultimate stability, security, and resilience even under turbulent market situations.

Mutuum Finance Introduces Lending & Borrowing Protocol

Mutuum Finance will soon launch its  lending and borrowing protocol, a milestone of its DeFi experience. V1 will be deployed in Q4 2025 on Sepolia Testnet, and will include a liquidity pool, mtToken, debt token, liquidator bot, etc. ETH and USDT will serve as collateral tokens for lending, borrowing, and collateralizing, and get integrated into a multi-purpose, user-friendly DeFi platform for ease of use and efficiency.

The Early-Stage DeFi Gem to Watch

While Ripple (XRP) captures the headlines with whale buys and wars of resistance close to the $3 mark, the most compelling opportunity in the market right now could be Mutuum Finance (MUTM). On sale in Phase 6 for as little as $0.035, already well over 60% sold out, MUTM has taken in over $17 million from over 16,820 investors. Its innovative dual-lending platform, dynamic LTV ratios, and risk-weighted collateral management place it among the few projects providing real DeFi utility rather than speculation. Its highly featured lending and borrowing protocol to debut on the Sepolia Testnet in Q4 2025 and possible integrations like a USD-pegged stablecoin on the horizon, Mutuum Finance is well positioned to be a key part of the next-generation DeFi market. Secure your allocation now before the presale price increases and demand is high during future phases.

For more information regarding Mutuum Finance (MUTM) please use the following links:

Website: https://mutuum.com/

Linktree: https://linktr.ee/mutuumfinance

Market Opportunity
Nowchain Logo
Nowchain Price(NOW)
$0.0012761
$0.0012761$0.0012761
+24.72%
USD
Nowchain (NOW) Live Price Chart
Disclaimer: The articles reposted on this site are sourced from public platforms and are provided for informational purposes only. They do not necessarily reflect the views of MEXC. All rights remain with the original authors. If you believe any content infringes on third-party rights, please contact service@support.mexc.com for removal. MEXC makes no guarantees regarding the accuracy, completeness, or timeliness of the content and is not responsible for any actions taken based on the information provided. The content does not constitute financial, legal, or other professional advice, nor should it be considered a recommendation or endorsement by MEXC.

You May Also Like

Vàng Cán Mốc Lịch Sử 5.000 USD: Khi Dự Báo Của CEO Bitget Gracy Chen Trở Thành Hiện Thực Và Tầm Nhìn Về Đích Đến 5.400 USD

Vàng Cán Mốc Lịch Sử 5.000 USD: Khi Dự Báo Của CEO Bitget Gracy Chen Trở Thành Hiện Thực Và Tầm Nhìn Về Đích Đến 5.400 USD

Thị trường tài chính toàn cầu vừa chứng kiến một khoảnh khắc lịch sử chấn động: Giá Vàng thế giới [...] The post Vàng Cán Mốc Lịch Sử 5.000 USD: Khi Dự Báo Của
Share
Vneconomics2026/02/10 16:26
Why the Bitcoin Boom Is Not Another Tulip Mania

Why the Bitcoin Boom Is Not Another Tulip Mania

Bitcoin is an amazing success story. It was only invented in January of 2009 and was only worth a tiny fraction of a cent for each token. Over just a few years
Share
Medium2026/02/10 15:44
Non-Opioid Painkillers Have Struggled–Cannabis Drugs Might Be The Solution

Non-Opioid Painkillers Have Struggled–Cannabis Drugs Might Be The Solution

The post Non-Opioid Painkillers Have Struggled–Cannabis Drugs Might Be The Solution appeared on BitcoinEthereumNews.com. In this week’s edition of InnovationRx, we look at possible pain treatments from cannabis, risks of new vaccine restrictions, virtual clinical trials at the Mayo Clinic, GSK’s $30 billion U.S. manufacturing commitment, and more. To get it in your inbox, subscribe here. Despite their addictive nature, opioids continue to be a major treatment for pain due to a lack of effective alternatives. In an effort to boost new drugs, the FDA released new guidelines for non-opioid painkillers last week. But making these drugs hasn’t been easy. Vertex Pharmaceuticals received FDA approval for its non-opioid Journavx in January, then abandoned a next generation drug after a failed clinical trial earlier this summer. Acadia similarly abandoned a promising candidate after a failed trial in 2022. One possible basis for non-opioids might be cannabis. Earlier this year, researchers at Washington University at St. Louis and Stanford published a study showing that a cannabis-derived compound successfully eased pain in mice with minimal side effects. Munich-based pharmaceutical company Vertanical is perhaps the furthest along in this quest. It is developing a cannabinoid-based extract to treat chronic pain it hopes will soon become an approved medicine, first in the European Union and eventually in the United States. The drug, currently called Ver-01, packs enough low levels of cannabinoids (including THC) to relieve pain, but not so much that patients get high. Founder Clemens Fischer, a 50-year-old medical doctor and serial pharmaceutical and supplement entrepreneur, hopes it will become the first cannabis-based painkiller prescribed by physicians and covered by insurance. Fischer founded Vertanical, with his business partner Madlena Hohlefelder, in 2017, and has invested more than $250 million of his own money in it. With a cannabis cultivation site and drug manufacturing plant in Denmark, Vertanical has successfully passed phase III clinical trials in Germany and expects…
Share
BitcoinEthereumNews2025/09/18 05:26